Lilly(US:LLY) Shanghai Securities·2025-11-11 10:27Investment Rating - The industry investment rating is "Overweight (Maintain)" [1] Core Viewpoints - The pharmaceutical and biotechnology industry is experiencing significant growth driven by advancements in AI technology, which enhances drug development efficiency and reduces costs [5][6] - Recent high-value collaborations in the AI pharmaceutical sector, such as those between companies like Insilico Medicine and Eli Lilly, highlight the increasing commercial value of domestic enterprises [3][4] - The AI+ healthcare market in China is projected to grow from 8.8 billion yuan in 2023 to 315.8 billion yuan by 2033, with a compound annual growth rate of 43% [5] Summary by Sections Industry Overview - The pharmaceutical and biotechnology sector is currently rated as "Overweight," indicating a favorable outlook compared to the benchmark index [1] - The industry has shown resilience and potential for growth, particularly in the context of AI-driven innovations [5] Recent Developments - Insilico Medicine has entered a strategic partnership with Eli Lilly, aiming to leverage AI technology for drug discovery, with potential earnings exceeding $100 million [3] - Crystal Technology has also formed a multi-target strategic collaboration with Eli Lilly, with a total agreement value of up to $345 million [4] Market Potential - The AI+ healthcare market in China is rapidly expanding, with the number of AI pharmaceutical companies reaching 105 by the end of 2024 [5] - The integration of AI in drug development is expected to shorten research cycles and improve success rates, supported by favorable government policies [6]